secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001104659-24-026324
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix raises $325M in private placement; appoints Pravin Dugel as Executive Chairman
--------------------------------------------------------------------------------

- Entered securities purchase agreement for 32.4M shares at $7.52/share and pre-funded warrants for 10.8M shares at $7.519/warrant, gross proceeds ~$325M.
- Preliminary unaudited cash $195.8M as of Dec 31, 2023; preliminary FY2023 net product revenue ~$57.9M.
- Pravin Dugel appointed Executive Chairman, effective Feb 21, 2024; receives $540K base salary, equity awards (1.28M options, 855K RSUs).
- CEO Antony Mattessich's employment agreement amended to improve severance benefits; Lead Independent Director Charles Warden appointed.
- Proceeds to accelerate AXPAXLI clinical development for wet AMD, including ongoing SOL-1 and planned SOL-2 Phase 3 trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924026324/0001104659-24-026324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924026324/tm246953d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-026324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer